KDR and prostate cancer: While our study is the first to examine the efficacy of cabozantinib in SCNPC, other preclinical prostate cancer studies in AR-active CRPC agree that VEGFR2 inhibition and disruption of the tumor vasculature could be principal components of cabozantinib-mediated tumor growth inhibition [36,41,42].